These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 25838513)

  • 41. Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial.
    Sidelmann Christensen A; Storgaard H; Hædersdal S; Hansen T; Knop FK; Vilsbøll T
    BMJ Open; 2018 Oct; 8(10):e022517. PubMed ID: 30287671
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Study protocol of the randomised placebo-controlled GLOBE trial:
    Hulst AH; Visscher MJ; Godfried MB; Thiel B; Gerritse BM; Scohy TV; Bouwman RA; Willemsen MGA; Hollmann MW; DeVries JH; Preckel B; Hermanides J
    BMJ Open; 2018 Jun; 8(6):e022189. PubMed ID: 29866735
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial.
    de Wit HM; Vervoort GM; Jansen HJ; de Galan BE; Tack CJ
    J Intern Med; 2016 Mar; 279(3):283-92. PubMed ID: 26553486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.
    Blonde L; Fainberg U; Kaltoft MS; Mosenzon O; Ramesh C; Rea R
    Diabetes Obes Metab; 2021 Oct; 23(10):2234-2241. PubMed ID: 34132018
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss.
    Ghanim H; Batra M; Green K; Abuaysheh S; Hejna J; Makdissi A; Borowski R; Kuhadiya ND; Chaudhuri A; Dandona P
    Diabetes Obes Metab; 2020 Oct; 22(10):1742-1752. PubMed ID: 32424935
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
    Dejgaard TF; von Scholten BJ; Christiansen E; Kreiner FF; Bardtrum L; von Herrath M; Mathieu C; Madsbad S;
    Diabetes Obes Metab; 2021 Dec; 23(12):2752-2762. PubMed ID: 34463425
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.
    Kuhadiya ND; Ghanim H; Mehta A; Garg M; Khan S; Hejna J; Torre B; Makdissi A; Chaudhuri A; Batra M; Dandona P
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3506-15. PubMed ID: 27490915
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption.
    Kårhus ML; Brønden A; Lyng Forman J; Haaber A; Vilsbøll T; Sonne DP; Knop FKK
    BMJ Open; 2021 Feb; 11(2):e044711. PubMed ID: 33558360
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial.
    Miras AD; Pérez-Pevida B; Aldhwayan M; Kamocka A; McGlone ER; Al-Najim W; Chahal H; Batterham RL; McGowan B; Khan O; Greener V; Ahmed AR; Petrie A; Scholtz S; Bloom SR; Tan TM
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):549-559. PubMed ID: 31174993
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study).
    Htike ZZ; Yates T; Brady EM; Webb D; Gray LJ; Swarbrick D; McCann GP; Khunti K; Davies MJ
    Cardiovasc Diabetol; 2016 Jul; 15(1):102. PubMed ID: 27440110
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
    Ahrén B; Hirsch IB; Pieber TR; Mathieu C; Gómez-Peralta F; Hansen TK; Philotheou A; Birch S; Christiansen E; Jensen TJ; Buse JB;
    Diabetes Care; 2016 Oct; 39(10):1693-701. PubMed ID: 27493132
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study.
    Elkind-Hirsch KE; Shaler D; Harris R
    J Diabetes Complications; 2020 Apr; 34(4):107548. PubMed ID: 32046931
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis.
    Dimitrios P; Michael D; Vasilios K; Konstantinos S; Konstantinos I; Ioanna Z; Konstantinos P; Spyridon B; Asterios K
    Curr Diabetes Rev; 2020; 16(4):313-326. PubMed ID: 31203802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin.
    Vanderheiden A; Harrison LB; Warshauer JT; Adams-Huet B; Li X; Yuan Q; Hulsey K; Dimitrov I; Yokoo T; Jaster AW; Pinho DF; Pedrosa I; Lenkinski RE; Pop LM; Lingvay I
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1798-806. PubMed ID: 26909799
    [TBL] [Abstract][Full Text] [Related]  

  • 56. GLP1 Receptor Agonist Liraglutide Is an Effective Therapeutic Option for Perioperative Glycemic Control in Type 2 Diabetes within Enhanced Recovery After Surgery (ERAS) Protocols.
    Kaneko S; Ueda Y; Tahara Y
    Eur Surg Res; 2018; 59(5-6):349-360. PubMed ID: 30537714
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
    Femminella GD; Frangou E; Love SB; Busza G; Holmes C; Ritchie C; Lawrence R; McFarlane B; Tadros G; Ridha BH; Bannister C; Walker Z; Archer H; Coulthard E; Underwood BR; Prasanna A; Koranteng P; Karim S; Junaid K; McGuinness B; Nilforooshan R; Macharouthu A; Donaldson A; Thacker S; Russell G; Malik N; Mate V; Knight L; Kshemendran S; Harrison J; Hölscher C; Brooks DJ; Passmore AP; Ballard C; Edison P
    Trials; 2019 Apr; 20(1):191. PubMed ID: 30944040
    [TBL] [Abstract][Full Text] [Related]  

  • 58. GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.
    Kadouh H; Chedid V; Halawi H; Burton DD; Clark MM; Khemani D; Vella A; Acosta A; Camilleri M
    J Clin Endocrinol Metab; 2020 May; 105(5):1552-63. PubMed ID: 31665455
    [TBL] [Abstract][Full Text] [Related]  

  • 59. GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.
    Crisci I; Aragona M; Politi KS; Daniele G; Del Prato S
    Acta Diabetol; 2015 Dec; 52(6):1129-33. PubMed ID: 26293127
    [TBL] [Abstract][Full Text] [Related]  

  • 60. INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6-month treatment with incretin-based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double-blind, randomised controlled trials (INVESTDIA).
    Kero J; Koskenniemi JJ; Karsikas S; Pokka T; Lou O; Toppari J; Veijola R
    Diabet Med; 2022 Oct; 39(10):e14913. PubMed ID: 35797241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.